Santhera Doubles Its DMD Portfolio By Taking Option On Vamorolone
Executive Summary
Deal Snapshot: Santhera acquires all rights to vamorolone from Idorsia, making it ReveraGen’s direct partner on the novel Duchenne muscular dystrophy therapy.
You may also be interested in...
Deal Watch: Kite Inks Novel AML Target Discovery Tie-Up With HiFiBiO
Continuing parent firm Gilead’s busy deal-making year in immuno-oncology, Kite gets option rights to new targets. Boehringer teams with Israel’s BiomX in IBD research.
Surprise As FDA Approves Sarepta’s Duchenne Drug Vyondys 53
The FDA has overcome doubts about the drug's safety and reversed its decision in just four months.
Santhera Braced For Another CHMP No In Duchenne
Santhera had a tumultuous 2017 and recovery is not going to be easy this year as its lead compound for the rare disease Duchenne muscular dystrophy is about to be rejected by regulators in Europe for a second time.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports